In a recent phase I dose escalation trial of the IDH1 inhibitor ivosidenib, which included all glioma grades and enhancing as well as nonenhancing tumors, ivosidenib reduced the volume and growth rates of only nonenhancing tumors [123]. This evidence concerns the gene IDH1 and central nervous system cancer.